Literature DB >> 19571803

Clinical challenges in addressing resistance to antimicrobial drugs in the twenty-first century.

E J Septimus1, K M Kuper.   

Abstract

It has been more than 60 years since Alexander Fleming discovered the drug that came to be known as penicillin. Antibiotics are now one of the most frequently used medications in the United States and are prescribed by medical professionals in almost every specialty. The past decade has seen an alarming increase in the number of pathogens that are resistant to antimicrobial drugs, in the hospital as well as in the community.(1) Among the gram-positive pathogens, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus species are the biggest threats. The situation is even more alarming with respect to gram-negative pathogens, especially because there are currently no late clinical trials involving new anti-infective drugs that are active against these pathogens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571803     DOI: 10.1038/clpt.2009.122

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.

Authors:  Kimberly D Leuthner; Celine Vidaillac; Chrissy M Cheung; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

2.  β-Lactamase-Producing Bacteria in Upper Respiratory Tract Infections.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2010-03       Impact factor: 3.725

Review 3.  Telavancin: a review of its use in patients with nosocomial pneumonia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

4.  Verigene® gram-positive blood culture nucleic acid test.

Authors:  Lesley J Scott
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

5.  Potential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis.

Authors:  Eanna Forde; Hilary Humphreys; Catherine M Greene; Deirdre Fitzgerald-Hughes; Marc Devocelle
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

6.  Treating acute cystitis with biodegradable micelle-encapsulated quercetin.

Authors:  Bi Lan Wang; Xiang Gao; Ke Men; Jinfeng Qiu; Bowen Yang; Ma Ling Gou; Mei Juan Huang; Ning Huang; Zhi Yong Qian; Xia Zhao; Yu Quan Wei
Journal:  Int J Nanomedicine       Date:  2012-05-08

7.  Next generation sequencing reveals the antibiotic resistant variants in the genome of Pseudomonas aeruginosa.

Authors:  Babu Ramanathan; Hassan Mahmood Jindal; Cheng Foh Le; Ranganath Gudimella; Arif Anwar; Rozaimi Razali; Johan Poole-Johnson; Rishya Manikam; Shamala Devi Sekaran
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

Review 8.  Immunoproteomics: the key to discovery of new vaccine antigens against bacterial respiratory infections.

Authors:  Ruth Dennehy; Siobhan McClean
Journal:  Curr Protein Pept Sci       Date:  2012-12       Impact factor: 3.272

Review 9.  Antimicrobial resistance in the food chain: a review.

Authors:  Claire Verraes; Sigrid Van Boxstael; Eva Van Meervenne; Els Van Coillie; Patrick Butaye; Boudewijn Catry; Marie-Athénaïs de Schaetzen; Xavier Van Huffel; Hein Imberechts; Katelijne Dierick; George Daube; Claude Saegerman; Jan De Block; Jeroen Dewulf; Lieve Herman
Journal:  Int J Environ Res Public Health       Date:  2013-06-28       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.